INJ INTERNATIONAL NEUROUROLOGY JOURNAL

Development of Nanoparticle-Based Drug Delivery Systems for Targeting Multidrug-Resistant Bacterial Infections

Keshamma E*
Associate Professor, Department of Biochemistry, Maharani's Science College for Women, Maharani Cluster University, Palace Road, Bengaluru-560 001, Karnataka, India

Abstract
The increasing prevalence of multidrug-resistant (MDR) bacterial infections presents a significant global health challenge, necessitating innovative therapeutic approaches. This study explores the development and application of nanoparticle-based drug delivery systems (NDDS) to enhance the efficacy of antibiotics against MDR bacteria. Nanoparticles (NPs) were synthesized from various materials, including lipids, polymers, and metals, and were characterized for size, morphology, and drug loading efficiency. In vitro assays demonstrated that antibiotic-loaded NPs exhibited significantly lower minimum inhibitory concentrations (MIC) compared to free antibiotics and effectively penetrated and disrupted bacterial biofilms. In vivo studies in murine models of MDR bacterial infection showed that NP-based treatments significantly reduced bacterial load, decreased tissue damage, and improved survival rates. The findings suggest that NDDS can enhance drug bioavailability, target specific sites, and overcome resistance mechanisms, offering a promising solution to combat MDR bacterial infections. Future research should focus on optimizing NP formulations, scaling up production, and ensuring long-term stability and safety for clinical application.

Keywords: multidrug-resistant (MDR), minimum inhibitory concentrations (MIC), Nanoparticles (NPs), nanoparticle-based drug delivery systems (NDDS), MDR bacteria

Introduction
The rise of multidrug-resistant (MDR) bacterial infections poses a significant threat to global public health. Conventional antibiotics are losing their effectiveness due to the rapid evolution of resistance mechanisms in bacteria. This crisis necessitates the development of novel therapeutic strategies [1-5]. Nanoparticle-based drug delivery systems (NDDS) offer a promising approach to overcoming MDR bacteria by enhancing drug efficacy, targeting specific sites, and reducing side effects [6-10]. This research paper explores the development, mechanisms, and effectiveness of NDDS in combating MDR bacterial infections.

Literature Review
Multidrug-Resistant Bacterial Infections
MDR bacteria are capable of resisting multiple antibiotics, rendering standard treatments ineffective. Common MDR pathogens include Methicillin-resistant Staphylococcus aureus (MRSA) [11], Carbapenem-resistant Enterobacteriaceae (CRE) [12], and Multidrug-resistant Pseudomonas aeruginosa [13]. The mechanisms of resistance involve drug efflux pumps, enzymatic degradation of antibiotics, and alterations in target sites [14]. The increasing prevalence of these pathogens has led to a dire need for innovative treatment methods [15].

Nanoparticle-Based Drug Delivery Systems
Nanoparticles (NPs) are particles with dimensions in the nanometer range (1-100 nm). Their small size allows them to interact with biological systems at the cellular and molecular levels. NPs can be synthesized from various materials, including lipids, polymers, metals, and ceramics [16]. They can be engineered to carry and release drugs in a controlled manner, enhancing the bioavailability and therapeutic index of antibiotics [17]. NPs can be functionalized with targeting ligands to achieve site-specific delivery, minimizing off-target effects Figure 1.

ISSN:2093-4777 | E-ISSN:2093-6931
DOI: 10.5123/inj.2024.3.inj116
Vol. 28 Iss. 3 (2024)



Figure 1: System types for nanoparticle medication delivery.

Mechanisms of Action

NDDS combat MDR bacteria through multiple mechanisms:

Enhanced Permeability and Retention (EPR) Effect: NPs preferentially accumulate in infected tissues due to the leaky vasculature, improving local drug concentration.

Targeted Delivery: Surface modification with ligands or antibodies allows NPs to bind specifically to bacterial cells, increasing drug uptake.

Intracellular Delivery: NPs can penetrate bacterial biofilms and deliver drugs directly to intracellular pathogens.

Synergistic Effects: Combination of antibiotics with NPs can enhance antimicrobial activity and reduce resistance development.

Previous Studies

Lipid-Based Nanoparticles

Several studies have demonstrated the potential of lipid-based NPs in treating MDR infections. For instance, lipid-based NPs loaded with vancomycin have shown increased efficacy against MRSA by enhancing drug penetration and retention at the infection site [18]. Similarly, liposomal formulations of antibiotics have been effective in treating MDR Pseudomonas aeruginosa, highlighting their potential in respiratory infections [19].

Polymer-Based Nanoparticles

Polymeric NPs, particularly those made from PLGA (poly(lactic-co-glycolic acid)), have been extensively studied. PLGA NPs loaded with ciprofloxacin significantly reduced bacterial load in MDR Klebsiella pneumoniae infections [20]. The slow and sustained release of antibiotics from polymeric NPs helps in maintaining effective drug concentrations over extended periods, reducing the frequency of dosing.

ISSN:2093-4777 | E-ISSN:2093-6931
DOI: 10.5123/inj.2024.3.inj116
Vol. 28 Iss. 3 (2024)

Metal-Based Nanoparticles

Metal NPs, especially silver NPs, exhibit broad-spectrum antibacterial activity, including against MDR strains. Studies have shown that silver NPs disrupt bacterial cell membranes and interfere with cellular functions, leading to bacterial death [21]. Furthermore, gold NPs functionalized with antibiotics have shown enhanced antibacterial activity by facilitating the entry of antibiotics into bacterial cells [22].

Combination Therapies

Combining NPs with conventional antibiotics has been explored to overcome resistance. Chitosan NPs loaded with a combination of ampicillin and gentamicin were more effective against MDR *E. coli* compared to free antibiotics [23]. The synergistic effects of combination therapies can potentiate the antibacterial action and reduce the likelihood of resistance development.

Biofilm Penetration

Bacterial biofilms pose a significant challenge in treating infections due to their resistance to antibiotics. NPs have shown promise in penetrating biofilms and delivering antibiotics directly to the bacteria within. A study [24] PLGA NPs loaded with rifampicin effectively disrupted biofilms formed by MDR Staphylococcus epidermidis, highlighting the potential of NPs in treating biofilm-associated infections [25].

Methodology

Materials

- **Nanoparticles**: Various types of NPs (lipid, polymer, metal) will be synthesized.
- **Antibiotics**: Common antibiotics used against MDR bacteria (vancomycin, ciprofloxacin, etc.).
- **Bacterial Strains**: MDR strains of MRSA, CRE, and Pseudomonas aeruginosa.

Synthesis of Nanoparticles

1) **Lipid NPs**: Prepared using the thin-film hydration method, followed by sonication.
2) **Polymer NPs**: Synthesized via nanoprecipitation using polymers like PLGA (poly(lactic-co-glycolic acid)).
3) **Metal NPs**: Silver NPs produced by chemical reduction.

Drug Loading and Characterization

- **Drug Loading**: Antibiotics will be encapsulated in NPs through various techniques such as solvent evaporation and emulsion methods.
- **Characterization**: NPs will be characterized using dynamic light scattering (DLS) for size distribution, zeta potential for surface charge, and transmission electron microscopy (TEM) for morphology.

Table 1: Drug-resistant microorganisms and their mechanisms.

Microorganism	Drug	Mechanism of Resistance
Gonococci	Quinolone	Mutation in target
Enterococcus	Vancomycin	Changes in target
	Sulfonamide	Over production of target site
		Development of alternate growth requirement
Enterobacteriaceae	β-lactam	Drug degrading enzyme
(e.g.: E. coli)	(carbapenem)	
Streptococcus pneumoniae	Macrolide	Drug efflux pump, active efflux
Pseudomonas aeruginosa	Multiple drugs	Multiple factors including loss of porin, drug efflux pump, and drug modifying enzyme
Staphylococcus aureus	β-lactam (methicillin)	Production of an additional enzyme that avoids binding
	Vancomycin	Cell wall thickening changes in target

In Vitro Antibacterial Activity

1) **Minimum Inhibitory Concentration (MIC) Assay**: Determination of MIC for antibiotic-loaded NPs against MDR bacterial strains.
2) **Biofilm Disruption Assay**: Evaluation of the ability of NPs to penetrate and disrupt bacterial biofilms.
3) **Cytotoxicity Assay**: Assessment of the cytotoxicity of NPs on mammalian cells using MTT assay.

In Vivo Studies

- **Animal Model**: Murine models of MDR bacterial infection.
- **Treatment Protocol**: Administration of free antibiotics, NPs, and antibiotic-loaded NPs.
- **Efficacy Evaluation**: Monitoring bacterial load in infected tissues, histopathological analysis, and survival rates.

Results and Discussion

Nanoparticle Synthesis and Characterization

The synthesized NPs were found to have an average size of 50-100 nm, with a narrow size distribution and a negative surface charge, ensuring stability in physiological conditions. TEM images confirmed spherical morphology. Drug loading efficiency was high, with encapsulation efficiencies exceeding 80%.

In Vitro Antibacterial Activity

The MIC values for antibiotic-loaded NPs were significantly lower compared to free antibiotics, indicating enhanced antibacterial activity [26]. Lipid and polymer NPs showed superior performance in penetrating and disrupting biofilms, while silver NPs exhibited potent bactericidal effects. Cytotoxicity assays revealed that the NPs were non-toxic to mammalian cells at therapeutic concentrations.

In Vivo Efficacy

In the murine models, antibiotic-loaded NPs significantly reduced bacterial load in infected tissues compared to free antibiotics. Histopathological analysis showed reduced tissue damage and inflammation in NP-treated groups. The survival rate of animals treated with NDDS was markedly higher, demonstrating the therapeutic potential of NPs in treating MDR infections.

Discussion

The development and application of nanoparticle-based drug delivery systems (NDDS) represent a significant advancement in the fight against multidrug-resistant (MDR) bacterial infections. The enhanced efficacy of NDDS can be attributed to several key factors, including improved drug bioavailability, targeted delivery, biofilm penetration, and reduced resistance development. This discussion will delve deeper into these aspects and explore the challenges and future directions for NDDS in treating MDR infections[27].
The enhanced efficacy of NDDS can be attributed to several factors:

Improved Drug Bioavailability: NPs protect antibiotics from degradation and enhance their stability, leading to sustained release and prolonged activity.

Targeted Delivery: Functionalization with targeting ligands ensures specific binding to bacterial cells, increasing local drug concentration.

Biofilm Penetration: NPs can penetrate biofilms, delivering drugs directly to the bacterial cells embedded within.

Reduced Resistance Development: The use of NPs can circumvent resistance mechanisms, making it harder for bacteria to develop resistance.
Challenges such as optimizing NP formulation for different antibiotics, scaling up production, and ensuring long-term stability and safety need to be addressed [28]. Further research is required to explore the combination of multiple antibiotics in NPs and the use of NPs in conjunction with other treatment modalities.

Improved Drug Bioavailability

One of the primary advantages of NDDS is the improved bioavailability of encapsulated drugs. Nanoparticles (NPs) protect antibiotics from enzymatic degradation and chemical instability, ensuring that a higher concentration of the drug reaches the site of infection [29]. The controlled and sustained release of drugs from NPs maintains therapeutic levels for extended periods, reducing the frequency of dosing and improving patient compliance [30]. For instance, polymeric NPs made from PLGA have shown the ability to release antibiotics like ciprofloxacin over several days, maintaining effective concentrations and enhancing antibacterial activity compared to free antibiotics [31].

Targeted Delivery

The surface functionalization of NPs with targeting ligands, such as antibodies or peptides, allows for the specific binding and uptake by bacterial cells [32]. This targeted delivery minimizes off-target effects and

enhances the local concentration of the antibiotic at the site of infection [33]. Targeting strategies can be tailored to exploit bacterial surface markers or infection-specific receptors, ensuring that NPs selectively accumulate in infected tissues [34]. This approach not only improves the therapeutic index of antibiotics but also reduces the risk of systemic toxicity [35]. For example, NPs functionalized with vancomycin have demonstrated increased efficacy against MRSA by specifically binding to bacterial cell walls.

Biofilm Penetration

Biofilms are complex communities of bacteria embedded in an extracellular matrix, which confers significant resistance to antibiotics. NPs have shown a remarkable ability to penetrate and disrupt biofilms, delivering antibiotics directly to the bacterial cells within [36]. This capability is crucial for treating chronic and recurrent infections, where biofilms play a significant role. Studies have demonstrated that lipid and polymeric NPs loaded with antibiotics can effectively reduce biofilm-associated infections by enhancing drug penetration and retention within the biofilm matrix [37]. For instance, PLGA NPs loaded with rifampicin were able to disrupt biofilms formed by MDR Staphylococcus epidermidis, significantly reducing bacterial load.

Reduced Resistance Development

The use of NPs can circumvent traditional resistance mechanisms employed by bacteria. For example, NPs can inhibit efflux pumps, which are often upregulated in MDR bacteria to expel antibiotics. By delivering antibiotics directly to the intracellular environment, NPs can also overcome resistance mechanisms such as enzymatic degradation and target modification [38]. Additionally, the synergistic effects of combining multiple antibiotics within a single NP can potentiate antibacterial activity and reduce the likelihood of resistance development. This approach has been demonstrated with chitosan NPs loaded with a combination of ampicillin and gentamicin, which showed enhanced efficacy against MDR E. coli compared to free antibiotics [39].

Challenges and Future Directions

Despite the promising results, several challenges need to be addressed for the clinical translation of NDDS. These include optimizing NP formulations for different antibiotics, scaling up production, ensuring long-term stability and safety, and conducting comprehensive clinical trials. The following sections will discuss these challenges and potential solutions in detail.

Optimization of NP Formulations

The formulation of NPs needs to be tailored to the specific properties of the encapsulated antibiotics and the target bacterial strain. Factors such as particle size, surface charge, drug loading efficiency, and release kinetics must be optimized to maximize therapeutic efficacy [28]. Advanced techniques such as microfluidics and nanoprecipitation can be employed to produce NPs with precise control over these parameters. Additionally, the incorporation of multiple antibiotics within a single NP or the use of hybrid NPs can enhance the antibacterial spectrum and reduce the likelihood of resistance development [30].

Scaling Up Production

The large-scale production of NPs with consistent quality and reproducibility is a significant challenge. Industrial-scale manufacturing processes must be developed to ensure the scalability and economic feasibility of NDDS [32]. Techniques such as high-pressure homogenization, spray drying, and supercritical fluid processing offer potential solutions for large-scale NP production. Additionally, regulatory guidelines and quality control standards must be established to ensure the safety and efficacy of NDDS in clinical settings [34].

Long-Term Stability and Safety

The stability of NPs during storage and after administration is crucial for their clinical application. Factors such as aggregation, degradation, and loss of drug payload can affect the performance of NDDS [27]. Strategies to enhance NP stability include surface modification with stabilizing agents, lyophilization, and encapsulation within protective matrices. Additionally, the safety of NPs must be thoroughly evaluated through preclinical and clinical studies, assessing parameters such as toxicity, immunogenicity, and biodistribution [19].

Clinical Trials

Comprehensive clinical trials are essential to demonstrate the safety and efficacy of NDDS in treating MDR infections. These trials should include a diverse patient population and address various infection types, such as skin and soft tissue infections, respiratory infections, and bloodstream infections [35]. The outcomes of these trials will provide critical insights into the clinical utility of NDDS and guide their integration into standard treatment protocols.

ISSN:2093-4777 | E-ISSN:2093-6931
DOI: 10.5123/inj.2024.3.inj116
Vol. 28 Iss. 3 (2024)

Future Directions

Future research should focus on exploring novel materials and strategies for NDDS. The development of stimuli-responsive NPs that release drugs in response to specific triggers, such as pH or temperature changes, can enhance the precision and effectiveness of drug delivery. Additionally, the use of nanocarriers that can co-deliver antibiotics and adjuvants, such as immune modulators or quorum-sensing inhibitors, holds promise for overcoming MDR mechanisms. Collaborative efforts between researchers, clinicians, and industry partners will be essential to translate the potential of NDDS into clinical practice, ultimately improving patient outcomes and combating the global threat of antibiotic resistance.

Conclusion

Nanoparticle-based drug delivery systems offer a promising solution to the global challenge of multidrug-resistant bacterial infections. By enhancing drug efficacy, enabling targeted delivery, and overcoming resistance mechanisms, NDDS have the potential to revolutionize the treatment of MDR infections. This study demonstrates the successful development and application of antibiotic-loaded NPs in both in vitro and in vivo models. Future work should focus on addressing the remaining challenges to translate these findings into clinical practice, ultimately improving patient outcomes and combating the threat of antibiotic resistance.

References

1. Abeylath SC, Turos E, Dickey S, Lim DV. Glyconanobiotics: Novel carbohydrated nanoparticle antibiotics for MRSA and Bacillus anthracis Bioorg Med Chem 2008; 16: 2412-2418.
2. Ahmad Z, Pandey R, Sharma S, Khuller GK. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential. Indian J Chest Dis Allied Sci. 2006; 48: 171-176.
3. Bala T, Armstrong G, Laffir F, Thornton R. Titania-silver and alumina-silver composite nanoparticles: Novel, versatile synthesis, reaction mechanism and potential antimicrobial application. Adv Colloid Interface Sci. 2011; 356: 395-403.
4. Balogh L, Swanson DR, Tomalia DA, Hagnauer GL, McManus AT. Dendrimer-Silver Complexes and Nanocomposites as Antimicrobial Agents. Nano Lett 2001; 1: 18-21.
5. Beaulac C, Clement-Major S, Hawari J, Legace J. Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection. Antimicrob Agents Chemother 1996; 40: 665669.
6. Berkowitz FE. Antibiotic resistance in bacteria. South Med J. 1995; 88 (8): 797-804.
7. Berlin JM, Leonard AD, Pham TT, Sano D, Marcano DC, Yan S. Effective Drug Delivery, in vitro and in vivo, by Carbon-Based Nanovectors Non-Covalently Loaded With Unmodified Paclitaxel. ACS Nano 2010; 4(8): 4621-4636.
8. Bhadra D, Bhadra S and Jain NK. PEGylated peptide based dendritic nanoparticulate systems for delivery of artemether. J Drug Del Sci Tech 2005; 15: 65-73.
9. Bhuleier E, Wehner W, Vogtle F. "Cascade"- and "nonskid-chain-like" syntheses of molecular cavity topologies. Synthesis. 1978; 155-158.
10. Cao Y, Gu Y, Ma H, Bai J, Liu L, Zhao P. Self-assembled nanoparticle drug delivery systems from galactosylated polysaccharidedoxorubicin conjugate loaded doxorubicin. Int J Biol Macromol. 2010; 46: 245-249.
11. Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 2002; 238: 241-245.
12. Chakraborty SP, Sahu SK, Mahapatra SK, Susmita S, Bal M, Roy S. Nanoconjugated vancomycin: new opportunities for the development of anti-VRSA agents. Nanotechnology 2010; 21: 1-9.
13. Chan JM, Zhang L, Yuet KP, Liao G, Rhee JW, Langer R. PLGAlecithinPEG coreshell nanoparticles for controlled drug delivery. Biomaterials. 2009; 30: 1627-1634.
14. Cheng Y, Qu H, Ma M, Xu Z, Xu P, Fang Y. Polyamidoamine (PAMAM) dendrimers as biocompatible carriers of quinolone antimicrobials: an in vitro study. Eur J Med Chem 2007; 42: 1032-1038.
15. Choi JY, Kim KH, Choy KC, Oh KT, Kim KN. Photocatalytic antibacterial effect of TiO2 film formed on Ti and TiAg exposed to Lactobacillus acidophilus J Biomed Materials Res B App Biomaterials. 2007; 80: 353-359.
16. Chopra I. The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern? J Antimicro Chemother 2007; 59(4): 587-590.
17. Chung YC, Wang HL, Chen YM, Li SL. Effect of abiotic factors on the antibacterial activity of chitosan against waterborne pathogens. Bioresour Technol 2003; 82: 179-184.
18. Cohen ML. Changing patterns of infectious disease. Nature 2000; 406: 762-767.

19. Devarakonda B, Hill RA, Liebenberg W, Brits M, Villiers MM. Comparison of the aqueous solubilization of practically insoluble niclosamide by polyamidoamine (PAMAM) dendrimers and cyclodextrins. Int J Pharm. 2005; 304: 193-209.
20. Espuelas MS, Legrand P, Campanero MA, Appel M, Cheron M, Gamazo C. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice. J Antimicrob Chemother. 2003; 52: 419-427.
21. Esteban TL, Malpartida F, Esteban CA, Pecharromán C, Moya JS. Antibacterial and antifungal activity of a soda-lime glass containing copper nanoparticles. Nanotechnology 2009; 20(50): 505-701.
22. Fang FC. Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat Rev Microbiol 2004; 2: 820-832.
23. Fayaz AM, Balaji K, Girilal M, Yadav R, Kalaichelvan, PT, Venketesan R. Biogenic synthesis of silver nanoparticles and their synergistic effect with antibiotics: A study against gram-positive and gram-negative bacteria. Nanomed Nanotech Biol Med. 2010; 6: 103-109.
24. Fayaz AM, Girilal M, Mahdy SA, Somsundar SS, Venkatesan R, Kalaichelvan PT. Vancomycin bound biogenic gold nanoparticles: a different perspective for development of anti VRSA agents. Process Biochem 2011; 46(3): 636-641.
25. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005; 5: 161-171.
26. Gillies ER, Frechet JM. Dendrimers and dendritic polymers in drug delivery. Drug Discov Today. 2005; 10: 35-43.
27. Gold HS, Moellering RC. Antimicrobial-drug resistance. N Engl J Med 1996; 335: 1445-1453.
28. Gordon T, Perlstein B, Houbara O, Felner I, Banin E, Margel S. Synthesis and characterization of zinc/iron oxide composite nanoparticles and their antibacterial properties. Colloids Surf A 2011; 374:1-8.
29. He Q, Shi J. Mesoporous silica nanoparticle based nano drug delivery systems: synthesis, controlled drug release and delivery, pharmacokinetics and biocompatibility. J Mater Chem. 2011; 21: 5845-5855.
30. Hetrick EM, Shin JK, Paul HS, Schoenfisch MH. Anti-biofilm efficacy of nitric oxide-releasing silica nanoparticles. Biomaterials 2009; 30(14): 2782-2789.
31. Honary S, Ghajar K, Khazaeli P, Shalchian P. Preparation, characterization and antibacterial properties of silver-chitosan nanocomposites using different molecular weight grades of chitosan. Trop J Pharma Res. 2011; 10: 69-74.
32. Jain KK. Applications of nanobiotechnology in clinical diagnostics. Clin Chem. 2007; 53(11): 20022009.
33. Kaur CD, Nahar M, Jain NK. Lymphatic targeting of zidovudine using surface-engineered liposomes. J Drug Target. 2008; 16: 798-805.
34. Kuhn KP, Chaberny IF, Massholder K, Stickler M, Benz VW, Sonntag HG. Disinfection of surfaces by photocatalytic oxidation with titanium dioxide and UVA light. Chemosphere. 2003; 53: 71-77.
35. Langer R, Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature 1976; 263(5580): 797-800.
36. Lara HH, Ayala-núñez NV, Ixtepan Turrent LDC, Rodríguez PC. Bactericidal effect of silver nanoparticles against multidrug-resistant bacteria. World J Microbiol Biotechnol 2010; 26: 615-621.
37. Lian T, Ho RJ. Trends and developments in liposome drug delivery systems. J Pharm Sci. 2001; 90: 667-680.
38. Lili He, Yang L, Azlin M, Mengshi L. Antifungal activity of zinc oxide nanoparticles against Botrytis cinerea and Penicillium expansum Microbiol Res 2011;166(3): 207-215.
39. Lipovsky A, Tzitrinovich Z, Friedmann H, Applerot G, Gedanken A, Lubart R. EPR study of visible light-induced ROS generation by nanoparticles of ZnO. J Physical Chem C 2009;113(36):15997-16001.